Ann: SNT to Trial New Cancer Indication Following MRFF Grant, page-7

Nothing new in this article, just more spin.
1. Nor is there mention of the losses that PTM would have been sitting on prior to costing averaging those losses down, still sitting on losses though.
2. No mention of how badly the PXS/SNT business was run with annual losses most years
3. As evidenced by the recent CR, retail investors are over the constant upbeat assessments and valuations while the share price heads down.
4. It's also evident that institutions are heading the same way with limited take up by them in the recent CR.

Few rolls of the dice left at SNT.